Navigation Links
Genetic variation linked to longer telomeres and lower risk of bladder cancer
Date:4/2/2011

ORLANDO, Fla. Using new genetic information, scientists have linked a commonly found human genetic variant with both longer telomeres and reduced risk of bladder cancer, according to findings presented at the AACR 102nd Annual Meeting 2011, held April 2-6, and simultaneously published in Cancer Prevention Research, a journal of the American Association for Cancer Research.

Jian Gu, Ph.D., assistant professor of epidemiology at The University of Texas MD Anderson Cancer Center, said the single-nucleotide polymorphism (SNP) rs398652 on 14q21 was linked to both longer telomeres and a 19 percent reduction in the risk of bladder cancer.

"This genetic locus is a determinant of both telomere length and bladder cancer risk, and long telomeres partially mediates the protective effect of the variant on bladder cancer," said Gu.

Gu and colleagues analyzed 300,000 SNPs in 459 healthy participants and found 15,120 of them that were associated with telomere length. They then conducted a further validation in 890 and 270 healthy participants and found four SNPs that were significantly associated with telomere length. Specific cross-analysis with genetic polymorphisms and risk of bladder cancer showed that rs398652 was associated with a 19 percent overall reduced risk of bladder cancer. Furthermore, smoking especially augmented the risk for bladder cancer in those people having the other genetic variant, associated with shorter telomeres.

AACR President Elizabeth H. Blackburn, Ph.D., the Morris Herzstein professor of biology and physiology in the department of biochemistry and biophysics at the University of California San Francisco, won the Nobel Prize in 2009 for her role in the discovery of telomeres and the enzyme telomerase.

In an accompanying editorial published in Cancer Prevention Research, Blackburn said that studies to date have not found a genetic link between both telomere length and cancer, which provides solid confirmation to population studies that suggested a role for telomeres in cancer development. Although she stressed that the effect of interventions to lengthen telomeres would need to be tested in prospective studies, she said the finding was a major research advancement.

"It has shed light on the biology of early cancers and their initiating events. These advances now create unprecedented opportunities for novel approaches directed at prevention and early interception of cancer's deadly trajectory," said Blackburn.

Blackburn will become immediate past president of the American Association for Cancer Research at 12:30 p.m. ET on Monday, April 4, 2011.

Both Gu and Blackburn will make presentations at an AACR Annual Meeting press conference on Saturday, April 2 at 2:00 p.m. ET in room W313 of the Orange County Convention Center. Reporters who cannot attend in person can participate using the following information:

  • U.S. & Canada: (888) 647-7462
  • International: (201) 604-0169
  • Access Code: 244081


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Genetic variation cuts bladder cancer risk, protects chromosome tips
2. Do At-Home Genetic Tests Tell Too Much and Explain Too Little?
3. Most Breast Tumors Have Unique Genetic Fingerprint, Study Finds
4. Canadian Journal of Cardiology publishes advice on genetic testing of inherited cardiac arrhythmias
5. Mouse cancer genome unveils genetic errors in human cancers
6. Home Genetic Tests May Need Doctors Involvement: Report
7. FDA Weighs Pros, Cons of Home Genetic Testing
8. Mix of Genetics and Stress Can Impair Mental Abilities
9. Leicester leads on heart attack genetic link discovery
10. Where are new schizophrenia drugs? Experts convene to explore genetic and epigenetic solutions
11. Researchers pinpoint genetic pathways involved in breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Research Institute (WCRI) officially opened registration today for its 33rd Annual Issues ... Boston, MA . , The theme of the conference is “Persistent Challenges and ...
(Date:12/8/2016)... Pa. (PRWEB) , ... December 08, 2016 , ... ... Medicine Southern Chester County, a Property owned by an affiliate of Seavest, has ... square foot Penn Medicine Southern Chester County ambulatory care center (ACC) was named ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, the ... (WIYM) campaign to inform dentists and patients about the safety issues related to dental ... market in the U.S. is projected to reach $6.4 billion in 2018 with more ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... access for customers and employees that are both engaging and easy to use. ... Smart Technology, the software company revealed today its plans to roll out new ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... has been recognized for adherence to the highest standards of trauma, maternity, ... organizations, announced the center's president and CEO, Dr. Daniel Messina. , Among the ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... , Dec. 9, 2016   Hudes Laser ... December featuring the multi-wavelength Astanza Trinity laser and ... specializes in laser tattoo removal, IPL hair removal, ... ultrasound therapy. Hudes Laser Aesthetica is setting high ... and promises to deliver effective, long-lasting ...
(Date:12/9/2016)... OSAKA, Japan , Dec. 9, 2016 ... ; President & Representative Director, CEO: Dr. ... with amyotrophic lateral sclerosis (ALS) given edaravone intravenously in ... functional loss as measured by the ALS Functional Rating ... th International Symposium on ALS/MND in ...
(Date:12/9/2016)... 9, 2016  Axovant Sciences Ltd. (NYSE: ... focused on the treatment of dementia, today announced ... Phase 2b trial evaluating treatment with intepirdine (RVT-101), ... donepezil plus placebo in people with mild-to-moderate Alzheimer,s ... intepirdine to treatment was associated with reduced progression ...
Breaking Medicine Technology: